DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
Add Yahoo as a preferred source to see more of our stories on Google. Dexcom is poised to share new data on the benefits of its continuous glucose monitoring technology (CGM), which the company says ...
DexCom's devices are incredibly valuable to diabetes patients. The company should continue to increase its addressable market. The stock's valuation looks as reasonable as it has in almost three years ...
DexCom reported second quarter earnings and issued guidance after the market closed on Wednesday. The company reported adjusted EPS of 43 cents beating analyst estimates of 39 cents. Get access to the ...
DexCom's Q3 performance shows impressive organic growth rates and increased revenue guidance for 2023. The company's strategic focus on international markets and expanding customer bases indicates ...
DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers.* Dexcom Smart Basal is FDA cleared and now the ...
Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results